Posted by Michael Rae on December 9, 2010 | Chief Science Officer's Team

Induced pluripotent stem cells (iPSCs) are among the most exciting recent developments in biomedicine, overcoming immunological and ethical issues associated with the use of embryonic stem cells (ESCs). However, reasonable doubt remains regarding whether iPSCs do in fact have the full biological and therapeutic potential of ESCs. Work at the Harvard Stem Cell Institute recently produced the first "all-iPSC" live mice, a milestone on the road to establishing full equivalence between the two methods.

Posted by Sarah Marr on December 9, 2010 | Founders

The global scientific community is increasingly recognizing the role of rejuvenation biotechnologies in addressing age-related disease. This week, Arizona-based businessman Jason Hope announced a $500,000 donation to SENS Foundation, a California-based non-profit organization that works to develop, promote and ensure widespread access to rejuvenation biotechnologies which comprehensively address age-related disease.

Posted by Mike Kope, CEO on December 8, 2010 | Founders

Last night, Peter Thiel hosted "Breakthrough Philanthropy", a dinner and presentation event showcasing eight non-profit organizations focused upon game-changing approaches to their fields. It was a wonderful opportunity for us to convey our message to a large group of entrepreneurs and philanthropists interested in the genuinely transformative. Our thanks to the Thiel Foundation, and the Seasteading Institute, for their efforts in creating that event.